about
Pyridostigmine bromide (PYR) alters immune function in B6C3F1 mice.Human Carboxylesterase 1 Stereoselectively Binds the Nerve Agent Cyclosarin and Spontaneously Hydrolyzes the Nerve Agent SarinEfficacy of antidotes (midazolam, atropine and HI-6) on nerve agent induced molecular and neuropathological changesTreatment of neuroterrorismSarin poisoning of a rescue team in the Matsumoto sarin incident in Japan.Effects of fosphenytoin on nerve agent-induced status epilepticus.Developing Health-Based Pre-Planning Clearance Goals for Airport Remediation Following Chemical Terrorist Attack: Introduction and Key Assessment Considerations.Treating exposure to chemical warfare agents: implications for health care providers and community emergency planning.Overcoming inhibitions.Nerve agents: a comprehensive review.Advances in toxicology and medical treatment of chemical warfare nerve agentsOpdA, a bacterial organophosphorus hydrolase, prevents lethality in rats after poisoning with highly toxic organophosphorus pesticidesIn vitro evaluation of the catalytic activity of paraoxonases and phosphotriesterases predicts the enzyme circulatory levels required for in vivo protection against organophosphate intoxications.Behavioural toxicity of anticholinesterases in humans and animals--a review.Recent advances in the treatment of organophosphorous poisonings.Development of a model for nerve agent inhalation in conscious rats.Effects of selected anticholinergics on acoustic startle response in rats.Carboxylesterase: specificity and spontaneous reactivation of an endogenous scavenger for organophosphorus compounds.Pharmacological antagonism of lethal effects induced by O-isobutyl S-[2-(diethylamino)ethyl]methylphosphonothioate.Use of the accelerating rotarod for assessment of motor performance decrement induced by potential anticonvulsant compounds in nerve agent poisoning.Nasal midazolam as a novel anticonvulsive treatment against organophosphate-induced seizure activity in the guinea pig.Function of plasma and microsomal enzymes in soman toxicity.Pharmacokinetic studies of intramuscular midazolam in guinea pigs challenged with soman.Efficacy comparison of scopolamine (SCP) and diazepam (DZ) against soman-induced lethality in guinea pigs.Cardiorespiratory function in nerve agent poisoned and oxime + atropine treated guinea-pigs: effect of pyridostigmine pretreatment.Aerosolized delivery of oxime MMB-4 in combination with atropine sulfate protects against soman exposure in guinea pigs.A primer on nerve agents: what the emergency responder, anesthesiologist, and intensivist needs to know.Pharmacokinetic and biodistribution study of eserine and pralidoxime chloride in rabbits following a single application of a transdermal patch.Changes of cholinesterase activities in the rat blood and brain after sarin intoxication pretreated with butyrylcholinesterase.Engineering resistance to 'aging' of phosphylated human acetylcholinesterase. Role of hydrogen bond network in the active center.Dramatic Increase in Cerebral Blood Flow following Soman Intoxication If Signs of Symptoms Can Be Seen
P2860
Q23917605-7C9C0E7D-4888-478F-8211-BFAEDC331550Q27658861-57122266-41BD-4670-A5CC-4A3B5D5EA9B8Q28383950-C0BB1B42-1FC0-4C6D-95D0-7FA7EAD4A0D4Q30224792-B2AF61F0-1D3A-4FB4-9F5B-4429C82CD543Q33820987-487C534D-4111-420A-A178-60287ABBF014Q34546555-3C8CEA2B-4EB7-485D-A31F-9B9CC01CAB43Q34614463-104C2768-432A-48AE-957B-2852DDAD4D29Q35033396-A484A838-B127-4414-BBAA-260CD4C0FCB0Q35037182-2F1BD88C-A026-4A04-BCA8-F24195A00C6CQ35702187-779DEAD1-4D39-4603-98DE-AE8E5528EAF6Q36565002-CA1FA5B3-1F7F-4196-9D81-A8228AC27D08Q36692584-C8FB5E1F-DB4B-43B4-A504-06390C2FC333Q39779108-D101AA2C-2E09-490D-AD4A-91E4EAD7BAFBQ40708426-6408D5C6-7172-42DC-BA5A-C4FBD4AC3D00Q42027845-BBDD6206-C328-4410-98FD-5AC45B3E01C4Q43357456-CCBF0D4A-A148-44BE-88B9-96DBA5D735B1Q43938375-8FA3621D-A074-4407-B6F5-B689B528DD16Q43938378-BEA6A609-33B4-4F7E-B1F1-258F2BE29AA2Q44098523-EE9803D5-953B-4B97-ADD3-9FE1576D70F7Q44313377-586FD550-700B-40E7-839B-1B307C1B037CQ44359186-F206C587-C8D5-444D-9DAA-AFB37F5E6F78Q44810493-54BC645B-E093-40CA-AD43-BBB7E07D1868Q44937269-6F44FB89-2E60-4DF7-AA30-232C50C7CAA6Q46675535-D5EF80F3-26DE-40C8-984A-BC24BCFDD0E5Q46735139-1E70CFED-EC9B-422C-B597-81A1632294E4Q46974653-3318E1ED-E355-4192-9F16-8A11DABE20E0Q47814209-13F86892-7351-4413-B2C1-A8C6AEB34E74Q48397101-BFBE4EDD-A148-4174-A039-C8D466629B64Q50673679-0038E3DF-B4F3-470A-827F-77904A0EA9ABQ54226185-F3681A17-733E-4750-AA7D-6D897B8C4DBEQ59104341-D915D615-17AF-4A30-A6C2-67B4BFDFD173
P2860
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Progress in medical defense against nerve agents.
@en
type
label
Progress in medical defense against nerve agents.
@en
prefLabel
Progress in medical defense against nerve agents.
@en
P1476
Progress in medical defense against nerve agents.
@en
P2093
P304
P356
10.1001/JAMA.1989.03430050065028
P407
P577
1989-08-01T00:00:00Z